INAB – in8bio, inc. (US:NASDAQ)
Stock Stats
News
IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting [Yahoo! Finance]
IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting
IN8bio to Present at Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference
IN8bio, Inc. (NASDAQ: INAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
IN8bio Reports Continued Durable Remissions in Phase 1 Trial of INB-200 in Plenary Oral Presentation at the Society for Neuro-Oncology (SNO) Annual Meeting [Yahoo! Finance]
Form 4 IN8BIO, INC. For: Dec 19 Filed by: Roemer Alan S.
Form 4 IN8BIO, INC. For: Dec 19 Filed by: Whitfill Travis
Form 4 IN8BIO, INC. For: Dec 19 Filed by: Brandt Peter C.
Form 4 IN8BIO, INC. For: Dec 19 Filed by: McCall Patrick
Form 4 IN8BIO, INC. For: Dec 19 Filed by: Epperly Corinne
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.